Artisan Partners Limited Partnership Ascendis Pharma A/S Transaction History

Artisan Partners Limited Partnership

$63.7 Billion
Q3 2024

A detailed history of Artisan Partners Limited Partnership transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Artisan Partners Limited Partnership holds 4,411,111 shares of ASND stock, worth $602 Million. This represents 1.03% of its overall portfolio holdings.

Number of Shares

4,411,111

Previous 4,295,029 2.7%

Holding current value

$602 Million

Previous $586 Million 12.46%

% of portfolio

1.03%

Previous 0.93%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$113.0 - $153.43 $13.1 Million - $17.8 Million	116,082 Added 2.7%	4,411,111 $659 Million
Q2 2024 Aug 12, 2024	SELL	$121.07 - $153.67 $167 Million - $212 Million	-1,376,905 Reduced 24.28%	4,295,029 $586 Million
Q1 2024 May 13, 2024	SELL	$123.45 - $159.4 $9.54 Million - $12.3 Million	-77,293 Reduced 1.34%	5,671,934 $857 Million
Q4 2023 Feb 12, 2024	SELL	$86.1 - $127.36 $21.2 Million - $31.4 Million	-246,181 Reduced 4.11%	5,749,227 $724 Million
Q3 2023 Nov 09, 2023	SELL	$86.5 - $103.97 $19.6 Million - $23.6 Million	-227,043 Reduced 3.65%	5,995,408 $561 Million
Q2 2023 Aug 10, 2023	SELL	$69.96 - $97.84 $43.5 Million - $60.9 Million	-622,290 Reduced 9.09%	6,222,451 $555 Million
Q1 2023 May 11, 2023	SELL	$104.9 - $126.78 $7.93 Million - $9.59 Million	-75,615 Reduced 1.09%	6,844,741 $734 Million
Q4 2022 Feb 10, 2023	SELL	$99.42 - $131.97 $22.8 Million - $30.2 Million	-229,137 Reduced 3.2%	6,920,356 $845 Million
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $27.2 Million - $35.7 Million	-323,593 Reduced 4.33%	7,149,493 $738 Million
Q2 2022 Aug 12, 2022	SELL	$78.08 - $117.61 $57.8 Million - $87 Million	-739,852 Reduced 9.01%	7,473,086 $695 Million
Q1 2022 May 13, 2022	BUY	$102.18 - $135.75 $27.8 Million - $37 Million	272,504 Added 3.43%	8,212,938 $964 Million
Q4 2021 Feb 11, 2022	BUY	$127.1 - $169.66 $19.8 Million - $26.4 Million	155,574 Added 2.0%	7,940,434 $1.07 Billion
Q3 2021 Nov 12, 2021	BUY	$112.67 - $176.92 $153 Million - $240 Million	1,355,453 Added 21.08%	7,784,860 $1.24 Billion
Q2 2021 Aug 12, 2021	BUY	$121.62 - $145.29 $46.5 Million - $55.6 Million	382,517 Added 6.33%	6,429,407 $846 Million
Q1 2021 May 11, 2021	BUY	$124.92 - $173.33 $34.9 Million - $48.4 Million	279,363 Added 4.84%	6,046,890 $779 Million
Q4 2020 Feb 10, 2021	BUY	$151.2 - $182.76 $23 Million - $27.8 Million	152,310 Added 2.71%	5,767,527 $962 Million
Q3 2020 Nov 12, 2020	BUY	$134.29 - $154.32 $213 Million - $244 Million	1,583,713 Added 39.28%	5,615,217 $867 Million
Q2 2020 Aug 12, 2020	BUY	$110.87 - $156.01 $163 Million - $230 Million	1,472,148 Added 57.52%	4,031,504 $596 Million
Q1 2020 May 12, 2020	BUY	$97.01 - $145.11 $39.1 Million - $58.5 Million	402,960 Added 18.69%	2,559,356 $288 Million
Q4 2019 Feb 12, 2020	BUY	$91.45 - $139.12 $1.53 Million - $2.33 Million	16,731 Added 0.78%	2,156,396 $300 Million
Q3 2019 Nov 12, 2019	BUY	$95.8 - $118.9 $52.3 Million - $65 Million	546,398 Added 34.29%	2,139,665 $206 Million
Q2 2019 Aug 09, 2019	BUY	$107.11 - $132.09 $49.5 Million - $61 Million	462,160 Added 40.86%	1,593,267 $183 Million
Q1 2019 May 10, 2019	BUY	$62.15 - $129.99 $47.5 Million - $99.3 Million	764,160 Added 208.25%	1,131,107 $133 Million
Q4 2018 Feb 12, 2019	BUY	$55.16 - $69.67 $7.46 Million - $9.42 Million	135,275 Added 58.39%	366,947 $23 Million
Q3 2018 Nov 13, 2018	BUY	$63.77 - $76.28 $9.22 Million - $11 Million	144,561 Added 165.95%	231,672 $16.4 Million
Q2 2018 Aug 10, 2018	BUY	$58.55 - $73.92 $5.1 Million - $6.44 Million	87,111 New	87,111 $5.8 Million

Others Institutions Holding ASND

# of Institutions

244

Shares Held

58.8M

Call Options Held

250K

Put Options Held

377K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Artisan Partners Limited Partnership with notifications on news.

Account

Artisan Partners Limited Partnership Ascendis Pharma A/S Transaction History